ACTRN12612000523808
Recruiting
未知
Patients with prostate cancer scheduled for a prostatectomy to have an Irreversible Electroporation procedure two to four weeks prior to the prostatectomy for the researchers to determine the effectiveness of irreversible electroporation on a small region in the prostate.
Flack Trustees0 sites6 target enrollmentMay 16, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- Flack Trustees
- Enrollment
- 6
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. 40 \- 75 years 2\. Histologically confirmed organ\-confined prostate cancer (clinical stage T1\-T2a) 3\. Gleason score 7 (3\+4 only) or less 4\. PSA less than or equal to 10 ng/ml 5\. No significant intravesical median lobe on ultrasound 6\. Able to visualize prostate gland adequately on transrectal US imaging 7\. No prostate calcification greater than 5 mm 8\. Ability of subject to stop anticoagulant and anti\-platelet therapy for 7 days prior and 7 days post procedure
Exclusion Criteria
- •1\. \<40, \>75 years of age 2\. High to medium risk subject with any one of the following: a) PSA greater than 10ng/ml, b) Gleason 7 (4\+3 only) or greater, c) Positive bone scan 3\. Other Conditions/Status a) Bleeding disorder as determined by prothrombin time (PT) \> 14\.5 seconds, partial thromboplastin time (PTT) \> 34 seconds, and platelet count \< 140/uL b) Active urinary tract infection (UTI”) c) History of bladder neck contracture d) Anaesthesia Surgical Assignment, category IV or greater e) Interest in future fertility f) History of inflammatory bowel disease g) Concurrent major debilitating illness h) Prior or concurrent malignancy 4\. Prior or current therapies a) Biologic therapy for prostate cancer b) Chemotherapy for prostate cancer c) Hormonal therapy for prostate cancer within 3 months of procedure d) Radiotherapy for prostate cancer e) Transurethral prostatectomy (TURP), urethral stent f) Prior major rectal surgery (except haemorrhoids) g) Inability or unwillingness to tolerate temporary cessation of concurrent anticoagulation therapy or anti\-platelet drugs for a period of 7days prior to procedure and up to 7 days after procedure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prostate cancer background, QOL, patient's satisfaction and treatment survey by Japan Prostate Cancer Study GroupProstate cancerJPRN-UMIN000004666J-CaP study group10,000
Completed
Not Applicable
Patient involvement in prostate cancer treatment decisionsProstate cancerCancerISRCTN97145188Dutch Cancer Society (The Netherlands)300
Not yet recruiting
Phase 2
A continence promotion intervention involving a pelvic floor muscle rehabilitation exercise program to reduce lower urinary tract, lower bowel symptoms and erectile dysfunction in men receiving radiation therapy with or without androgen deprivation therapy (ADT): A Pilot StudyProstate Cancer TreatmentLower Urinary Tract sequelae to radiation therapy with or without androgen deprivation therapyLower Bowel Dysfunction as sequelae to radiation therapy with or without androgen deprivation therapyErectile Dysfunction as sequelae to radiation therapy with or without androgen deprivation therapyCancer - ProstatePhysical Medicine / Rehabilitation - PhysiotherapyRenal and Urogenital - Other renal and urogenital disordersACTRN12612000527864niversity of Newcastle40
Completed
Phase 1
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - ProstateACTRN12615000912583Peter MacCallum Cancer Centre30
Recruiting
Not Applicable
PROCOG: Investigating Cognitive Problems in Men with Prostate CancerProstate CancerCognitive problemsCancer - ProstateMental Health - Studies of normal psychology, cognitive function and behaviourMental Health - AnxietyMental Health - DepressionMental Health - Other mental health disordersACTRN12621001608853Macquarie University150